InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Sagimet Biosciences Inc.

SGMT Clue Score32
United States Fiscal year ends December CIK 0001400118
$8.93 +0.11% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $8.93 +12.75% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 14 Jul 2023. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2022Operating income−31.1Net income−30.5EPS, diluted−165.20Fiscal year 2023Revenue2.0Operating income−30.7Net income−27.9EPS, diluted−2.66Fiscal year 2024Operating income−54.5Net income−45.6EPS, diluted−1.45Fiscal year 2025Operating income−56.9Net income−51.0EPS, diluted−1.58
FY2022FY2023FY2024FY2025
Revenue n/a 2.0 n/a n/a
Growth
Operating income −31.1 −30.7 −54.5 −56.9
Net income −30.5 −27.9 −45.6 −51.0
Growth
EPS, diluted −165.20 −2.66 −1.45 −1.58

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2022Fiscal year 2023Operating margin−1,537.0%Net margin−1,393.8%Fiscal year 2024Fiscal year 2025
FY2022FY2023FY2024FY2025
Operating margin n/a −1,537.0% n/a n/a
Net margin n/a −1,393.8% n/a n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2022Operating cash flow−24.5Fiscal year 2023Operating cash flow−23.8Fiscal year 2024Operating cash flow−42.4Fiscal year 2025Operating cash flow−45.7
FY2022FY2023FY2024FY2025
Operating cash flow −24.5 −23.8 −42.4 −45.7

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2022Cash0.2Shareholders’ equity−187.0Fiscal year 2023Cash75.1Shareholders’ equity91.1Fiscal year 2024Cash75.8Shareholders’ equity155.8Fiscal year 2025Cash35.0Shareholders’ equity111.4
FY2022FY2023FY2024FY2025
Cash 0.2 75.1 75.8 35.0
Shareholders’ equity −187.0 91.1 155.8 111.4

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Operations
−24.5 −23.8 −42.4 −45.7
Growth
Investment
−32.0 12.6 −61.7 4.6
Financing
−0.1 86.2 104.8 0.3

Capital expenditure, dividends and buybacks are shown as money out, so negative.